Having the ability to investigate and evaluate hypotheses about the behaviour of molecules of therapeutic interest prior to costly experimentation can help save time and money. That’s why Accelrys has improved and developed a suite of predictive scientific applications and services. Enhancements to its Discovery Studio 4.0 include capabilities to identify mutation sites for disulphide bridges, enabling molecular biologists and antibody engineers to improve the stability of novel biologics. It also includes improvements to both scalability and performance in long-duration (nanosecond) simulations and fully re-engineered non-bond interaction analysis, accelerating structure-based drug design in small molecules research. Accelrys Inc.
Print this page
Related